Member Info for Uncanny

Yes, its only a low volume technical rally at present, so RNS’s and yes there are many to come and it could be boom time.

Yes.

Lol, so if we want some positive enthusiasm, Pfizer equivalent purchase of 201 as compared to Xtandi would be worth about £14 per share for VAL! I want the price to incrementally go up and conaolidate - buyers, then a fee profiteers, then again buyers and repeat. That way the rise is sustainable

“The initial agreement, based on the issuance of convertible notes and warrants, allows Oncology Venture to receive up to SEK 200 million distributed over twenty (20) tranches during a period of twenty-four (24) months. The initial agreement provided that the Investor could call up to five (5) of the twenty (20) tranches. Oncology Venture and the Investor have now agreed that Oncology Venture holds all calls and thereby has full control over how many tranches will be called upon and when they are called, subject to the satisfaction of the conditions set out in the initial agreement.” Thats the sort of deal that l am expecting over 2 years.

Financing deal done IMHO Max which at 3p puts us on an equal footing to other P2 AIM juniors bios at £20 - £25 million market cap, maybe VAL is worth more? Noise - wow didn’t realise Pfizer paid that much!

Taff, I agree that between 3p - 5p is fair if the funding is in place PLUS JV’s to take to commercial completion. Then it is all down to the success of the compounds through CT and any deals that are struck which will take it beyond 3p - 5p IMHO

Well done. Hopefully back up to a penny soon, then more favourable ABO finance deal done, 201 escalation update and possibly more meat on the bone for 401 and 101 JV. Exciting stuff!

Want to see a but of profit taking so we can steady for the second wave upwards. A few coming in now which is quite healthy

Maddog, that was the value of the 54 shares, not a SP prediction but that would be very nice!

Personally with a good 201 update, financing secured and what we have to date with patented IP, progress, LOI’s JV’s et al, VAL Should be at circa 3p IMHO, which shoukd be the platform that they spring from. Still hugely undervalued. 201 and revised financing should be the catalyst to get things really going as this doubling in SP is simply technical which excites me as we haven't got the news yet!

I think we can say death spiral over if we get the same (or similar) to Onocogy Ventures, agreed with ABO and not a forced dilution as previously. I am confident but not certain of course that this is where ABO and VAL are anchoring talks based on this past amendment in March this year. The first for both parties didn’t work so good to see a common-sense solution and this will firmly put all the doomsayers to bed! Bring on 201 etc.

This sort of deal for VAL would be awesome! “The initial agreement, based on the issuance of convertible notes and warrants, allows Oncology Venture to receive up to SEK 200 million distributed over twenty (20) tranches during a period of twenty-four (24) months. The initial agreement provided that the Investor could call up to five (5) of the twenty (20) tranches. Oncology Venture and the Investor have now agreed that Oncology Venture holds all calls and thereby has full control over how many tranches will be called upon and when they are called, subject to the satisfaction of the conditions set out in the initial agreement.”

No, but while you’re here it helps a lot!

Hopefully, we are now moving in the right direction and VAL have said to ABO, enough is enough, you’re killing our SP, lets vary the Funding deal plus hey, have a look at these 201 figures! Have VAL got something lined up for 201 outsourcing a license deal? AIMHO DYOR

Just moved at the end!

Chelsea7, l think it goes without saying that ABO will have signed an NDA to see data provided by VAL to support the cancellation of the first finance deal and supersede it with more favourable terms for VAL in terms of controlling unnecessary dilution, wouldn’t you? All IMHO of course.

No Roses, Valju is correct.

Because EHGOS have been selling millions everyday in May. Overhang gone now, so no more downward pressure on the SP and hence the upturn Friday and 129 million volume, plus here today as well.

The rest and pretty clear! ....grants in major territories (announced 25/04/18) and these include USA, Europe, Japan and Australia. Additional patent applications are pending in several other countries. VAL301 VAL301, is derived from ValiRx's lead compound, VAL201 and is currently in late-stage pre-clinical development as a non-invasive, effective treatment for the non-cancerous, but hugely debilitating gynaecological condition, endometriosis. The compound is derived from VAL201 and its potential therapeutic approach is based on the same mode of action. VAL301 is currently in late-stage pre-clinical development (announced 17/07/18) for the hugely debilitating gynaecological condition, endometriosis, which is characterised by endometrial-like tissue found outside of the uterine cavity. The condition represents one of the major causes of female infertility. In pre-clinical studies, the compound has been shown to reduce endometrial lesions by up to 50 per cent. and the Company believes it is well placed for further study as a potential treatment. In addition, the Company's pre-clinical studies have also revealed that VAL301's treatment of this hormone-induced disorder is potentially without side effects, such as loss of bone density and fertility (announced 17/07/18). This additional advantage represents a potentially significant further break-through development in the medical treatment for this illness and for other gynaecological conditions. VAL301 received a US patent grant and receipt of patent allowances covering China and the Russian Federation (announced 17/07/18 and 31/01/19 respectively). These provide protection for the compound in three of the most populous nations in the World. Dr Satu Vainikka, CEO of ValiRx, commented: "The pre-clinical and clinical development of the VAL201 compound is very encouraging and from scientific and therapeutic perspectives, we look forward keenly to examining both the trial's results and analysis later this year and the opportunities for VAL201's further development and commercialisation. As with any small biotechnology company such as ValiRx, its patent portfolio and trial results represent its main assets and value drivers. I am delighted therefore with the solid foundation our global patent protection and trial progress represents, which will I am confident be of future benefit to all patients and stakeholders".

You mean this on Valju: ValiRx PLC Update on VAL201 & VAL301 Development Progress Source: UK Regulatory (RNS & others) TIDMVAL RNS Number : 5129T ValiRx PLC 21 March 2019 VALIRX PLC ("ValiRx" or the "Company") UPDATE ON VAL201 & VAL301 CLINICAL AND PRE-CLINICAL DEVELOPMENT PROGRESS. London, UK., 21 March 2019: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, is pleased to provide an update on the development of its therapeutic drugs, VAL201 and VAL301 regarding their clinical and pre-clinical progress. VAL201 The Company's leading anti-cancer therapeutic, VAL201, is a peptide with a unique mechanism of action, which was first developed by academics partly with support from Cancer Research UK. It is currently in a Phase l/ll Clinical Trial at University College London Hospital ("UCLH") for the treatment of advanced prostate cancer and potentially other indications of hormone-induced unregulated growth. ValiRx have established that VAL201 is safe and well tolerated at doses of up to 4mg/kg and the Company can report that it has seen primary evidence of the drug's activity in prostate cancer. Based on these results, the MHRA approved an extension to the trial (announced 18/12/17), allowing for an intra-patient dose escalation of up to 16mg/kg. This segment of the trial is in the concluding stages of its Phase l/ll (announced 17/10/18) and is progressing with patients to establish the maximum tolerated acute dose in Humans (MTD). This part of the study is also further establishing potential efficacy levels and pharmacokinetic / pharmacodynamic profiles as well, providing supporting information with respect to the optimal therapeutic regimes to be tested in the subsequent late stage clinical trials. An interim inspection of the trial's output indicates that the compound is and continues to perform as predicted from the pre-clinical findings. On conclusion of the current Phase l/ll trial, the full data set will be analysed by third-party experts and the compound's profile and behaviour will be published. The completion of the trial is a mandatory milestone prior to permission being given for further pre-market authorisation efficacy studies (Phase II/III). After reaching a conclusion based upon analysis of the results from this dose-ranging study, the Company will then decide whether to seek a partner or licencing agreement with a pharma company or proceed to a proprietary pivotal Phase IIb/III study. The results from the trial are expected at the end of H1 2019 and analysis of the data is anticipated to start Q3 2019, following which a full analysis of the results and findings will be published. The board is currently evaluating the optimum strategies for adding value during the study and commercialising the compound. The Company will keep shareholders and stakeholders informed of progress. VAL201 has received a number of paten